SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · A cluster of insider transactions at Alnylam Pharmaceuticals over the…

ALNYLAM PHARMACEUTICALS, INC. · CLUSTER filed Mar 2, 2026 at 19:00 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Mar 2, 2026 at 19:00 ET

A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO and EVP of R&D totaling $204K, alongside non-cash grant and derivative exercise events involving top executives including the CEO and CFO. The sales are small in absolute value and represent a negligible fraction of the company's $43.4B market cap, while the other transactions are routine equity compensation activities.

  • CSO Kevin Fitzgerald sold $91,483 in shares (289 shares at $316.55) on March 3, 2026
  • EVP of R&D Pushkal Garg sold $112,443 in shares (355 shares at $316.74) on March 3, 2026
  • CEO Yvonne Greenstreet received a non-cash award of 13,844 shares and exercised 5,921 shares via derivative on February 27 and March 2
  • CFO Jeffrey Poulton and other C-suite executives received non-cash awards and exercised derivatives with no open-market impact

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access